A team of researchers at UVA Health has joined a national trial that is looking at repurposing drugs to treat mild to moderate cases of COVID-19. This trial, called ACTIV-6, is a national double-blind study that wants to enroll 15,000 participants from across the country. It’s looking at Fluvoxamine, a medication typically used to treat depression and was identified for possible use against COVID based on sepsis research. It also is considering Ivermectin, which is used in human and horse versions to treat parasitic infections.